Q-omics provides the consensus-scored MFSD6L profile across patient tissues and cancer cell-line models. MFSD6L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MFSD6L is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MFSD6L RNA expression shows 14,089 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, KIRC, and TGCT as cancer lineages where MFSD6L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MFSD6L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MFSD6L survival associations across molecular data types. MFSD6L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MFSD6L RNA expression–survival associations across cancer types. High MFSD6L expression shows unfavorable associations in UCEC and LGG, but favorable associations in SKCM, READ, SCLC and KICH. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MFSD6L RNA expression.
This table summarizes MFSD6L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MFSD6L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MFSD6L shows lower tumor expression in KIRC, KIRP, HNSC, COAD, THCA and KICH. The KIRC box plot shows higher MFSD6L RNA expression in normal versus tumor tissue (log2 FC = −2.712, t-test p < 0.001).
This table shows molecular features associated with MFSD6L in patient tissues and cancer cell lines. In patient samples, MFSD6L shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MFSD6L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
